全文获取类型
收费全文 | 3314174篇 |
免费 | 256669篇 |
国内免费 | 5880篇 |
专业分类
耳鼻咽喉 | 48406篇 |
儿科学 | 104895篇 |
妇产科学 | 91572篇 |
基础医学 | 473069篇 |
口腔科学 | 96825篇 |
临床医学 | 294958篇 |
内科学 | 645216篇 |
皮肤病学 | 69430篇 |
神经病学 | 272907篇 |
特种医学 | 130131篇 |
外国民族医学 | 1170篇 |
外科学 | 499544篇 |
综合类 | 74611篇 |
现状与发展 | 2篇 |
一般理论 | 1214篇 |
预防医学 | 266855篇 |
眼科学 | 78333篇 |
药学 | 250196篇 |
5篇 | |
中国医学 | 6420篇 |
肿瘤学 | 170964篇 |
出版年
2018年 | 35418篇 |
2017年 | 26684篇 |
2016年 | 29328篇 |
2015年 | 33270篇 |
2014年 | 46697篇 |
2013年 | 71372篇 |
2012年 | 98156篇 |
2011年 | 104032篇 |
2010年 | 60496篇 |
2009年 | 56913篇 |
2008年 | 97945篇 |
2007年 | 104973篇 |
2006年 | 105811篇 |
2005年 | 103115篇 |
2004年 | 99074篇 |
2003年 | 95260篇 |
2002年 | 94052篇 |
2001年 | 147599篇 |
2000年 | 152639篇 |
1999年 | 129217篇 |
1998年 | 37581篇 |
1997年 | 33767篇 |
1996年 | 33697篇 |
1995年 | 32440篇 |
1994年 | 30511篇 |
1993年 | 28368篇 |
1992年 | 104314篇 |
1991年 | 101422篇 |
1990年 | 98777篇 |
1989年 | 95404篇 |
1988年 | 88639篇 |
1987年 | 87179篇 |
1986年 | 82943篇 |
1985年 | 79351篇 |
1984年 | 60010篇 |
1983年 | 51390篇 |
1982年 | 31153篇 |
1981年 | 27706篇 |
1979年 | 56784篇 |
1978年 | 40127篇 |
1977年 | 34043篇 |
1976年 | 32170篇 |
1975年 | 34445篇 |
1974年 | 41919篇 |
1973年 | 40037篇 |
1972年 | 37811篇 |
1971年 | 35072篇 |
1970年 | 32937篇 |
1969年 | 30974篇 |
1968年 | 28726篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
992.
993.
994.
Is atrial fibrillation an inflammatory disorder? 总被引:2,自引:0,他引:2
I read with great interest the excellent review on the influenceof inflammation in the pathogenesis of atrial fibrillation (AF)by Boos 相似文献
995.
996.
997.
Kevin L Taylor Rhonda K Oates Ron Grane Douglas W Leaman Ernest C Borden Daniel J Lindner 《Journal of interferon & cytokine research》2006,26(5):353-361
Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma. To investigate the ability of IFNs to inhibit angiosarcoma, we used two transformed murine endothelial cell lines that form angiosarcomas in vivo. SVR and MS1-VEGF cell lines express oncogenic H-ras or vascular endothelial growth factor (VEGF), respectively. IFN-alpha1,8, which is active against murine and human cells, inhibited SVR and MS1-VEGF proliferation in vitro by 40% at 10(3) U/mL (p = 0.028). In vivo, IFN-alpha1,8 inhibited SVR tumor volume by 71% (p = 0.047) and MS1-VEGF volume by 79% (p = 0.003). Tumor-induced angiogenesis was decreased in SVR tumors by 52% (p = 0.005) and in MS1-VEGF tumors by 58% (p = 0.001). Sera from IFN-alpha1,8-treated mice bearing either SVR or MS1-VEGF tumors demonstrated a 5-fold increase in IP-10/CXCL10 (p = 0.001), an IFN-induced antiangiogenic protein. Both recombinant IP-10 and IFN-alpha1,8 inhibited human umbilical vein endothelial cell (HUVEC) vessel formation in the fibrin gel assay, a three-dimensional culture model of angiogenesis, by 56% at 25 ng/mL and 50% at 1.2 ng/mL, respectively (p < 0.001). An IP-10 blocking antibody restored vessel formation to 80% of untreated controls (p = 0.001). Given the magnitude of the in vivo response, these data suggested that the antitumor effects of IFN-alpha1,8 were likely mediated through angiogenesis inhibition rather than solely by direct inhibition of tumor cell proliferation. 相似文献
998.
Â. C. Volpini M. J. Marques S. Lopes dos Santos G. L. Machado-Coelho W. Mayrink A. J. Romanha 《Clinical microbiology and infection》2006,12(8):815-818
This study examined the ability of PCR to amplify Leishmania DNA, stored on Giemsa-stained slides, from American cutaneous leishmaniasis (ACL) patients. In total, 475 slides stored for up to 36 years were obtained from an outpatient clinic in a Brazilian ACL-endemic region, and Leishmania DNA was amplified from 395 (83.2%) of the DNA samples using primers specific for the minicircle kinetoplast DNA. Restriction fragment length polymorphism analysis of these amplicons demonstrated that Leishmania (Viannia) braziliensis was the only species present in these samples. The results demonstrated that archived Giemsa-stained slides can provide a Leishmania DNA source for performing clinical and epidemiological studies of leishmaniasis. 相似文献
999.
1000.
Henk R Franke F Froukje Snaaijer Paul W H Houben Marius J van der Mooren 《Gynecological endocrinology》2006,22(12):692-697
OBJECTIVE: To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women. METHODS: In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score). RESULTS: Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups. CONCLUSIONS: Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss. 相似文献